Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
Matching Patients With Hematologic Malignancy to Adequate Clinical Trials
|3||Enrolling by invitation||
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid Cancer
† Study has passed its completion date and status has not been verified in more than two years.